Canntab Therapeutics

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2016, Canntab Therapeutics has already paid €1.89 in dividends. The last payout was in April 2016.

Financials

In the last year, Canntab Therapeutics had revenue of €216.23k and net profit of -€2.72m

(EUR)	2022	YoY
Revenue	216.23k	-
Gross profit	-692.12k	287.83%
Net profit	-2.72m	9.22%
EBITDA	-1.83m	11.23%

Fundamentals

Metric	Value
Market capitalization	€3.53k
Number of shares	38.91m
52-week high/low	€0.00662 - €0.0000907
Dividends	No
Beta	1.42
P/E ratio	-0.05
PEG ratio	0.00
P/B ratio	-0.61
P/S ratio	0.66

Company profile

Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.